|Assembly Actions - Lowercase
Senate Actions - UPPERCASE
|Apr 12, 2019||referred to consumer protection|
senate Bill S5169
Current Bill Status - In Senate Committee Consumer Protection Committee
- In Committee
- On Floor Calendar
- Passed Senate
- Passed Assembly
- Delivered to Governor
- Signed/Vetoed by Governor
S5169 (ACTIVE) - Details
S5169 (ACTIVE) - Sponsor Memo
BILL NUMBER: S5169 SPONSOR: BIAGGI TITLE OF BILL: An act to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs PURPOSE OF BILL: Enacts the "Manufacturer Disclosure and Transparency Act" to bring disclosure and transparency to the pay-for-delay deals that harm consum- ers by delaying generic drug competition with brand-name drugs. SUMMARY OF SPECIFIC PROVISIONS: Section 1 creates the title of the bill. Section 2 of the bill requires each pharmaceutical manufacturer doing business in this state that manufactures a brand-name prescription drug and enters into an agreement with another pharmaceutical manufacturer
S5169 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ S. 5169 A. 7196 2019-2020 Regular Sessions S E N A T E - A S S E M B L Y April 12, 2019 ___________ IN SENATE -- Introduced by Sen. BIAGGI -- read twice and ordered print- ed, and when printed to be committed to the Committee on Consumer Protection IN ASSEMBLY -- Introduced by M. of A. DenDEKKER -- read once and referred to the Committee on Consumer Affairs and Protection AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. This act shall be known and may be cited as the "manufac- turer disclosure and transparency act". § 2. The general business law is amended by adding a new section 396- rrr to read as follows: § 396-RRR. DELAY OF INTRODUCTION OF GENERIC MEDICATIONS. 1. (A) EACH PHARMACEUTICAL MANUFACTURER DOING BUSINESS IN THIS STATE THAT MANUFAC- TURES A BRAND NAME PRESCRIPTION DRUG AND ENTERS INTO AN AGREEMENT WITH ANOTHER PHARMACEUTICAL MANUFACTURER FOR THE PURPOSE OF DELAYING OR PREVENTING SUCH OTHER MANUFACTURER FROM INTRODUCING A GENERIC SUBSTITUTE FOR SUCH DRUG INTO THE MARKETPLACE SHALL, NOT LATER THAN THIRTY DAYS AFTER ENTERING INTO SUCH AGREEMENT, SEND NOTICE TO THE ATTORNEY GENERAL, IN A FORM AND MANNER PRESCRIBED BY THE ATTORNEY GENERAL, DISCLOSING THE NAME OF SUCH DRUG, THE WHOLESALE PRICE, THE DISEASE SUCH DRUG IS COMMON- LY PRESCRIBED TO TREAT, THE MANUFACTURER OF SUCH DRUG, THE NAME OF THE GENERIC MANUFACTURER, AND THE LENGTH OF THE DELAY. (B) THE ATTORNEY GENERAL SHALL, NO LATER THAN THIRTY DAYS AFTER RECEIVING A NOTICE PURSUANT TO PARAGRAPH (A) OF THIS SUBDIVISION, SHARE THE INFORMATION WITH THE DRUG UTILIZATION REVIEW BOARD ESTABLISHED UNDER SECTION THREE HUNDRED SIXTY-NINE-BB OF THE SOCIAL SERVICES LAW, ALL EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.
By contributing or voting you agree to the Terms of Participation and verify you are over 13.